Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology

Mary Cushman; Ellen S. O'Meara; Susan R. Heckbert; Neil A. Zakai; Wayne Rosamond; Aaron R. Folsom

doi:10.1016/j.thromres.2016.06.012

Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology

Mary Cushman, Ellen S. O'Meara, Susan R. Heckbert, Neil A. Zakai, Wayne Rosamond, Aaron R. Folsom

Epidemiology & Community Health

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Objective Obesity is an important venous thrombosis (VT) risk factor but the reasons for this are unclear. Materials and methods In a cohort of 20,914 individuals aged 45 and older without prior VT, we calculated the relative risk (RR) of VT over 12.6 years follow-up according to baseline body size measures, and studied whether associations were mediated by biomarkers of hemostasis and inflammation that are related to adiposity. Results Greater levels of all body size measures (weight, height, waist, hip circumference, calf circumference, body-mass index, waist-hip ratio, fat mass and fat-free mass) were associated with increased risk of VT, with 4th versus 1st quartile RRs of 1.5-3.0. There were no multiplicative interactions of biomarkers with obesity status. Adjustment for biomarkers associated with VT risk and body size (factors VII and VIII, von Willebrand factor, partial thromboplastin time, D-dimer, C-reactive protein and factor XI) only marginally lowered, or did not impact, the RRs associated with body size measures. Conclusions Greater body size, by multiple measures, is a risk factor for VT. Associations were not mediated by circulating levels of studied biomarkers suggesting that body size relates to VT because of physical factors associated with blood flow, not the hypercoagulability or inflammation associated with adiposity.

Original language	English (US)
Pages (from-to)	127-132
Number of pages	6
Journal	Thrombosis Research
Volume	144
DOIs	https://doi.org/10.1016/j.thromres.2016.06.012
State	Published - Aug 1 2016

Bibliographical note

Funding Information:
ARIC is carried out as a collaborative study supported by the National Heart, Lung, and Blood Institute (NHLBI) contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C. CHS was supported by contracts HHSN268201200036C, HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grant HL080295 from the NHLBI, with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS) and AG023629 from the National Institute on Aging (NIA). The Longitudinal Investigation of Thromboembolism Etiology was funded by R01-HL59367. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding source had no role in the study design, manuscript writing or decision to publish.

Publisher Copyright:
© 2016 Elsevier Ltd All rights reserved.

Keywords

Abbreviations ARIC Atherosclerosis Risk in Communities
BMI body-mass index
CHS Cardiovascular Health Study
VT venous thrombosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.thromres.2016.06.012

http://europepmc.org/articles/pmc4980192

Find It

Find It at U of M Libraries

Cite this

@article{f91ed23700a2491bbdee81ba6201e025,

title = "Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology",

abstract = "Objective Obesity is an important venous thrombosis (VT) risk factor but the reasons for this are unclear. Materials and methods In a cohort of 20,914 individuals aged 45 and older without prior VT, we calculated the relative risk (RR) of VT over 12.6 years follow-up according to baseline body size measures, and studied whether associations were mediated by biomarkers of hemostasis and inflammation that are related to adiposity. Results Greater levels of all body size measures (weight, height, waist, hip circumference, calf circumference, body-mass index, waist-hip ratio, fat mass and fat-free mass) were associated with increased risk of VT, with 4th versus 1st quartile RRs of 1.5-3.0. There were no multiplicative interactions of biomarkers with obesity status. Adjustment for biomarkers associated with VT risk and body size (factors VII and VIII, von Willebrand factor, partial thromboplastin time, D-dimer, C-reactive protein and factor XI) only marginally lowered, or did not impact, the RRs associated with body size measures. Conclusions Greater body size, by multiple measures, is a risk factor for VT. Associations were not mediated by circulating levels of studied biomarkers suggesting that body size relates to VT because of physical factors associated with blood flow, not the hypercoagulability or inflammation associated with adiposity.",

keywords = "Abbreviations ARIC Atherosclerosis Risk in Communities, BMI body-mass index, CHS Cardiovascular Health Study, VT venous thrombosis",

author = "Mary Cushman and O'Meara, {Ellen S.} and Heckbert, {Susan R.} and Zakai, {Neil A.} and Wayne Rosamond and Folsom, {Aaron R.}",

note = "Funding Information: ARIC is carried out as a collaborative study supported by the National Heart, Lung, and Blood Institute (NHLBI) contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C. CHS was supported by contracts HHSN268201200036C, HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grant HL080295 from the NHLBI, with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS) and AG023629 from the National Institute on Aging (NIA). The Longitudinal Investigation of Thromboembolism Etiology was funded by R01-HL59367. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding source had no role in the study design, manuscript writing or decision to publish. Publisher Copyright: {\textcopyright} 2016 Elsevier Ltd All rights reserved.",

year = "2016",

month = aug,

day = "1",

doi = "10.1016/j.thromres.2016.06.012",

language = "English (US)",

volume = "144",

pages = "127--132",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis

T2 - The Longitudinal Investigation of Thromboembolism Etiology

AU - Cushman, Mary

AU - O'Meara, Ellen S.

AU - Heckbert, Susan R.

AU - Zakai, Neil A.

AU - Rosamond, Wayne

AU - Folsom, Aaron R.

N1 - Funding Information: ARIC is carried out as a collaborative study supported by the National Heart, Lung, and Blood Institute (NHLBI) contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C. CHS was supported by contracts HHSN268201200036C, HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grant HL080295 from the NHLBI, with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS) and AG023629 from the National Institute on Aging (NIA). The Longitudinal Investigation of Thromboembolism Etiology was funded by R01-HL59367. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding source had no role in the study design, manuscript writing or decision to publish. Publisher Copyright: © 2016 Elsevier Ltd All rights reserved.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Objective Obesity is an important venous thrombosis (VT) risk factor but the reasons for this are unclear. Materials and methods In a cohort of 20,914 individuals aged 45 and older without prior VT, we calculated the relative risk (RR) of VT over 12.6 years follow-up according to baseline body size measures, and studied whether associations were mediated by biomarkers of hemostasis and inflammation that are related to adiposity. Results Greater levels of all body size measures (weight, height, waist, hip circumference, calf circumference, body-mass index, waist-hip ratio, fat mass and fat-free mass) were associated with increased risk of VT, with 4th versus 1st quartile RRs of 1.5-3.0. There were no multiplicative interactions of biomarkers with obesity status. Adjustment for biomarkers associated with VT risk and body size (factors VII and VIII, von Willebrand factor, partial thromboplastin time, D-dimer, C-reactive protein and factor XI) only marginally lowered, or did not impact, the RRs associated with body size measures. Conclusions Greater body size, by multiple measures, is a risk factor for VT. Associations were not mediated by circulating levels of studied biomarkers suggesting that body size relates to VT because of physical factors associated with blood flow, not the hypercoagulability or inflammation associated with adiposity.

AB - Objective Obesity is an important venous thrombosis (VT) risk factor but the reasons for this are unclear. Materials and methods In a cohort of 20,914 individuals aged 45 and older without prior VT, we calculated the relative risk (RR) of VT over 12.6 years follow-up according to baseline body size measures, and studied whether associations were mediated by biomarkers of hemostasis and inflammation that are related to adiposity. Results Greater levels of all body size measures (weight, height, waist, hip circumference, calf circumference, body-mass index, waist-hip ratio, fat mass and fat-free mass) were associated with increased risk of VT, with 4th versus 1st quartile RRs of 1.5-3.0. There were no multiplicative interactions of biomarkers with obesity status. Adjustment for biomarkers associated with VT risk and body size (factors VII and VIII, von Willebrand factor, partial thromboplastin time, D-dimer, C-reactive protein and factor XI) only marginally lowered, or did not impact, the RRs associated with body size measures. Conclusions Greater body size, by multiple measures, is a risk factor for VT. Associations were not mediated by circulating levels of studied biomarkers suggesting that body size relates to VT because of physical factors associated with blood flow, not the hypercoagulability or inflammation associated with adiposity.

KW - Abbreviations ARIC Atherosclerosis Risk in Communities

KW - BMI body-mass index

KW - CHS Cardiovascular Health Study

KW - VT venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84975215477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975215477&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2016.06.012

DO - 10.1016/j.thromres.2016.06.012

M3 - Article

C2 - 27328432

AN - SCOPUS:84975215477

SN - 0049-3848

VL - 144

SP - 127

EP - 132

JO - Thrombosis Research

JF - Thrombosis Research

ER -

Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this